New molecules modulating bone metabolism - new perspectives in the treatment of osteoporosis.
作者： I. ZOFKOVA , J. BLAHOS
DOI: 10.33549/PHYSIOLRES.933720
关键词:
摘要: In this review the authors outline traditional antiresorptive pharmaceuticals, such as bisphosphonates, monoclonal antibodies against RANKL, SERMs, well a drug with an anabolic effect on skeleton, parathormone. However, there is also focus non-traditional strategies used in therapy for osteolytic diseases. The newest antiosteoporotic pharmaceuticals increase osteoblast differentiation via BMP signaling (harmine), or stimulate osteogenic of mesenchymal stem cells through Wnt/beta-catenin (icarrin, isoflavonoid caviunin, sulfasalazine). A certain promise treatment osteoporosis shown by molecules targeting non-coding microRNAs (which are critical osteoclastogenesis) those stimulating activity epigenetic mechanisms. Vitamin D metabolites have specific potencies, modulating skeleton not only mineralization, but markedly direct effects bone microstructure.
sci-hub.st 参考文章(50)
Yuichiro Yamada, Diabetes mellitus and osteoporosis. Incretin as a coordinator of glucose and bone metabolism Clinical calcium. ,vol. 22, pp. 1353- 1358 ,(2012)
Yusuke Yamasaki, Keita Nagira, Mari Osaki, Hideki Nagashima, Hiroshi Hagino, Effects of eldecalcitol on cortical bone response to mechanical loading in rats BMC Musculoskeletal Disorders. ,vol. 16, pp. 158- 158 ,(2015) , 10.1186/S12891-015-0613-3
P Kushwaha, V Khedgikar, J Gautam, P Dixit, R Chillara, A Verma, R Thakur, D P Mishra, D Singh, R Maurya, N Chattopadhyay, P R Mishra, R Trivedi, A novel therapeutic approach with Caviunin-based isoflavonoid that en routes bone marrow cells to bone formation via BMP2/Wnt-β-catenin signaling. Cell Death and Disease. ,vol. 5, ,(2014) , 10.1038/CDDIS.2014.350
Leif Mosekilde, Ove Torring, Lars Rejnmark, Emerging Anabolic Treatments in Osteoporosis Current Drug Safety. ,vol. 6, pp. 62- 74 ,(2011) , 10.2174/157488611795684712
Fabrice Mac-Way, Andrea Trombetti, Christian Noel, Marie-Hélène Lafage-Proust, None, Giant osteoclasts in patients under bisphosphonates. BMC Clinical Pathology. ,vol. 14, pp. 31- 31 ,(2014) , 10.1186/1472-6890-14-31
Satoshi Takeda, Susan Y. Smith, Tatsuya Tamura, Hitoshi Saito, Fumiaki Takahashi, Rana Samadfam, Solomon Haile, Nancy Doyle, Koichi Endo, Long-term treatment with eldecalcitol (1α, 25-dihydroxy-2β- (3-hydroxypropyloxy) vitamin D3) suppresses bone turnover and leads to prevention of bone loss and bone fragility in ovariectomized rats. Calcified Tissue International. ,vol. 96, pp. 45- 55 ,(2015) , 10.1007/S00223-014-9937-5
S. Ishtiaq, I. Fogelman, G. Hampson, Treatment of post-menopausal osteoporosis: beyond bisphosphonates Journal of Endocrinological Investigation. ,vol. 38, pp. 13- 29 ,(2015) , 10.1007/S40618-014-0152-Z
Karen van der Meijden, Paul Lips, Marjolein van Driel, Annemieke C. Heijboer, Engelbert A. J. M. Schulten, Martin den Heijer, Nathalie Bravenboer, Primary human osteoblasts in response to 25-hydroxyvitamin D3, 1,25-dihydroxyvitamin D3 and 24R,25-dihydroxyvitamin D3. PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0110283
Takayuki Yonezawa, Ji-Won Lee, Ayaka Hibino, Midori Asai, Hironori Hojo, Byung-Yoon Cha, Toshiaki Teruya, Kazuo Nagai, Ung-Il Chung, Kazumi Yagasaki, Je-Tae Woo, Harmine promotes osteoblast differentiation through bone morphogenetic protein signaling Biochemical and Biophysical Research Communications. ,vol. 409, pp. 260- 265 ,(2011) , 10.1016/J.BBRC.2011.05.001
Ivana Zofkova, Martin Hill, Long-term 1,25(OH)2 vitamin D therapy increases bone mineral density in osteopenic women. Comparison with the effect of plain vitamin D. Aging Clinical and Experimental Research. ,vol. 19, pp. 472- 477 ,(2007) , 10.1007/BF03324733